Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents

Journal of Medicinal Chemistry

Volumn 59, Issue 18, 2016, Pages 8326-8344

  Li, Xiaokang ^a   Wang, Huan ^b   Lu, Zhengyu ^a   Zheng, Xinyu ^a   Ni, Wei ^a   Zhu, Jin ^a   Fu, Yan ^b   Lian, Fulin ^b   Zhang, Naixia ^b   Li, Jian ^a   Zhang, Haiyan ^b   Mao, Fei ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 (4 ((DIPROPYLAMINO)METHYL) 1H IMIDAZOL 1 YL)PYRIMIDIN 4 YL) 3 ETHYLTHIOUREA; 1 ETHYL 3 (6 (4 (PYRROLIDIN 1 YLMETHYL) 1H IMIDAZOL 1 YL)PYRIMIDIN 4 YL)THIOUREA; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; COPPER; PYRIMIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; NEUROPROTECTIVE AGENT; PROTEIN AGGREGATE; THIOUREA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CHELATION; CHEMICAL MODIFICATION; COGNITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MEMORY; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN AGGREGATION; SCOPOLAMINE-INDUCED AMNESIA; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CELL LINE; CHOLINESTERASE INHIBITORS; COGNITION; DRUG DESIGN; HUMANS; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; PROTEIN AGGREGATES; REACTIVE OXYGEN SPECIES; THIOUREA;

EID: 84988726135     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00636     Document Type: Article

References (70)

1. Prince, M.; Albanese, E.; Guerchet, M. World Alzheimer Report 2014. Dementia and Risk Reduction: An Analaysis of Protective and Modifiable Factors. Alzheimer's Disease International: London, 2014; pp 1-99.
2. Emmerzaal, T. L.; Kiliaan, A. J.; Gustafson, D. R. 2003-2013: a decade of body mass index, Alzheimer's disease, and dementia J. Alzheimer's Dis. 2015, 43, 739-755 10.3233/JAD-141086
3. Cummings, J. L.; Zhong, K.; Morstorf, T. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures Alzheimer's Res. Ther. 2014, 6, 37 10.1186/alzrt269
4. Lee, S.; Zheng, X.; Krishnamoorthy, J.; Savelieff, M. G.; Park, H. M.; Brender, J. R.; Kim, J. H.; Derrick, J. S.; Kochi, A.; Lee, H. J.; Kim, C.; Ramamoorthy, A.; Bowers, M. T.; Lim, M. H. Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease J. Am. Chem. Soc. 2014, 136, 299-310 10.1021/ja409801p
5. Derrick, J. S.; Kerr, R. A.; Nam, Y.; Oh, S. B.; Lee, H. J.; Earnest, K. G.; Suh, N.; Peck, K. L.; Ozbil, M.; Korshavn, K. J.; Ramamoorthy, A.; Prabhakar, R.; Merino, E. J.; Shearer, J.; Lee, J.-Y.; Ruotolo, B. T.; Lim, M. H. A redox-active, compact molecule for cross-linking amyloidogenic peptides into nontoxic, off-pathway aggregates: In vitro and in vivo efficacy and molecular mechanisms J. Am. Chem. Soc. 2015, 137, 14785-14797 10.1021/jacs.5b10043
6. Baptista, F. I.; Henriques, A. G.; Silva, A. M. S.; Wiltfang, J.; da Cruz e Silva, O. A. B. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease ACS Chem. Neurosci. 2014, 5, 83-92 10.1021/cn400213r
7. Li, S.-Y.; Wang, X.-B.; Xie, S.-S.; Jiang, N.; Wang, K. D. G.; Yao, H.-Q.; Sun, H.-B.; Kong, L.-Y. Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease Eur. J. Med. Chem. 2013, 69, 632-646 10.1016/j.ejmech.2013.09.024
8. Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; Serrano, F. G.; Sabate, R.; Juarez-Jimenez, J.; Perez, B.; Luque, F. J.; Andrisano, V.; Clos, M. V.; Inestrosa, N. C.; Munoz-Torrero, D. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents J. Med. Chem. 2014, 57, 2549-2567 10.1021/jm401824w
9. Nepovimova, E.; Uliassi, E.; Korabecny, J.; Pena-Altamira, L. E.; Samez, S.; Pesaresi, A.; Garcia, G. E.; Bartolini, M.; Andrisano, V.; Bergamini, C.; Fato, R.; Lamba, D.; Roberti, M.; Kuca, K.; Monti, B.; Bolognesi, M. L. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant Effects J. Med. Chem. 2014, 57, 8576-8589 10.1021/jm5010804
10. Rochais, C.; Lecoutey, C.; Gaven, F.; Giannoni, P.; Hamidouche, K.; Hedou, D.; Dubost, E.; Genest, D.; Yahiaoui, S.; Freret, T.; Bouet, V.; Dauphin, F.; Sopkova de Oliveira Santos, J.; Ballandonne, C.; Corvaisier, S.; Malzert-Freon, A.; Legay, R.; Boulouard, M.; Claeysen, S.; Dallemagne, P. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: The design of donecopride J. Med. Chem. 2015, 58, 3172-3187 10.1021/acs.jmedchem.5b00115
11. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651 10.1016/S1359-6446(04)03163-0
12. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372 10.1021/jm7009364
13. Wang, Z.; Wang, Y.; Wang, B.; Li, W.; Huang, L.; Li, X. Design, synthesis, and evaluation of orally available clioquinol-moracin M hybrids as multitarget-directed ligands for cognitive improvement in a rat model of neurodegeneration in Alzheimer's disease J. Med. Chem. 2015, 58, 8616-8637 10.1021/acs.jmedchem.5b01222
14. Bartus, R. T.; Dean, R. L., 3rd; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction Science 1982, 217, 408-414 10.1126/science.7046051
15. Perry, E.; Walker, M.; Grace, J.; Perry, R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999, 22, 273-280 10.1016/S0166-2236(98)01361-7
16. Coyle, J. T.; Price, D. L.; DeLong, M. R. Alzheimer's disease: a disorder of cortical cholinergic innervation Science 1983, 219, 1184-1190 10.1126/science.6338589
17. Francis, P. T.; Palmer, A. M.; Snape, M.; Wilcock, G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol., Neurosurg. Psychiatry 1999, 66, 137-147 10.1136/jnnp.66.2.137
18. Green, K. D.; Fridman, M.; Garneau-Tsodikova, S. hChAT: A Tool for the chemoenzymatic generation of potential acetyl/butyrylcholinesterase inhibitors ChemBioChem 2009, 10, 2191-2194 10.1002/cbic.200900309
19. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease Lancet 2011, 377, 1019-1031 10.1016/S0140-6736(10)61349-9
20. Holzgrabe, U.; Kapkova, P.; Alptuezuen, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration Expert Opin. Ther. Targets 2007, 11, 161-179 10.1517/14728222.11.2.161
21. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Arch. Pharmacal Res. 2013, 36, 375-399 10.1007/s12272-013-0036-3
22. Lo, D.; Grossberg, G. T. Use of memantine for the treatment of dementia Expert Rev. Neurother. 2011, 11, 1359-1370 10.1586/ern.11.132
23. Scarpini, E.; Schelterns, P.; Feldman, H. Treatment of Alzheimer's disease; current status and new perspectives Lancet Neurol. 2003, 2, 539-547 10.1016/S1474-4422(03)00502-7
24. Blennow, K.; de Leon, M. J.; Zetterberg, H. Alzheimer's disease Lancet 2006, 368, 387-403 10.1016/S0140-6736(06)69113-7
25. Yankner, B. A. Mechanisms of neuronal degeneration in Alzheimer's disease Neuron 1996, 16, 921-932 10.1016/S0896-6273(00)80115-4
26. Kepp, K. P. Bioinorganic chemistry of Alzheimer's disease Chem. Rev. 2012, 112, 5193-5239 10.1021/cr300009x
27. Lee, H. J.; Korshavn, K. J.; Kochi, A.; Derrick, J. S.; Lim, M. H. Cholesterol and metal ions in Alzheimer's disease Chem. Soc. Rev. 2014, 43, 6672-6682 10.1039/C4CS00005F
28. Savelieff, M. G.; DeToma, A. S.; Derrick, J. S.; Lim, M. H. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease Acc. Chem. Res. 2014, 47, 2475-2482 10.1021/ar500152x
29. Duce, J. A.; Bush, A. I. Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics Prog. Neurobiol. (Oxford, U. K.) 2010, 92, 1-18 10.1016/j.pneurobio.2010.04.003
30. Ayton, S.; Lei, P.; Bush, A. I. Metallostasis in Alzheimer's disease Free Radical Biol. Med. 2013, 62, 76-89 10.1016/j.freeradbiomed.2012.10.558
31. Praticò, D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal Trends Pharmacol. Sci. 2008, 29, 609-615 10.1016/j.tips.2008.09.001
32. Lee, H. P.; Zhu, X.; Casadesus, G.; Castellani, R. J.; Nunomura, A.; Smith, M. A.; Lee, H. G.; Perry, G. Antioxidant approaches for the treatment of Alzheimer's disease Expert Rev. Neurother. 2010, 10, 1201-1208 10.1586/ern.10.74
33. Fernández-Bachiller, M. I.; Pérez, C.; González-Muñoz, G. C.; Conde, S.; López, M. G.; Villarroya, M.; García, A. G.; Rodríguez-Franco, M. I. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties J. Med. Chem. 2010, 53, 4927-4937 10.1021/jm100329q
34. Kochi, A.; Eckroat, T. J.; Green, K. D.; Mayhoub, A. S.; Lim, M. H.; Garneau-Tsodikova, S. A novel hybrid of 6-chlorotacrine and metal-amyloid-β modulator for inhibition of acetylcholinesterase and metal-induced amyloid-β aggregation Chem. Sci. 2013, 4, 4137-4145 10.1039/c3sc51902c
35. Wu, M.-Y.; Esteban, G.; Brogi, S.; Shionoya, M.; Wang, L.; Campiani, G.; Unzeta, M.; Inokuchi, T.; Butini, S.; Marco-Contelles, J. Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation Eur. J. Med. Chem. 2016, 121, 864-879 10.1016/j.ejmech.2015.10.001
36. Li, S.-Y.; Wang, X.-B.; Xie, S.-S.; Jiang, N.; Wang, K. D. G.; Yao, H.-Q.; Sun, H.-B.; Kong, L.-Y. Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease Eur. J. Med. Chem. 2013, 69, 632-646 10.1016/j.ejmech.2013.09.024
37. Bolea, I.; Gella, A.; Unzeta, M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors J. Neural Transm. 2013, 120, 893-902 10.1007/s00702-012-0948-y
38. Mohamed, T.; Yeung, J. C. K.; Vasefi, M. S.; Beazely, M. A.; Rao, P. P. N. Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: Application to a pyrimidine-2,4-diamine template Bioorg. Med. Chem. Lett. 2012, 22, 4707-4712 10.1016/j.bmcl.2012.05.077
39. Mohamed, T.; Zhao, X.; Habib, L. K.; Yang, J.; Rao, P. P. N. Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: Dual activity as cholinesterase and Aβ-aggregation inhibitors Bioorg. Med. Chem. 2011, 19, 2269-2281 10.1016/j.bmc.2011.02.030
40. Mohamed, T.; Yeung, J. C.K.; Rao, P. P.N. Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation Bioorg. Med. Chem. Lett. 2011, 21, 5881-5887 10.1016/j.bmcl.2011.07.091
41. Mohamed, T.; Rao, P. P. Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 3606-3609 10.1016/j.bmcl.2010.04.108
42. Orysyk, S. I.; Bon, V. V.; Pekhnyo, V. I.; Zborovskii, Y. L.; Orysyk, V. V.; Vovk, M. V. Synthesis, structure and spectral characteristics of Ni(II), Pd(II) and Zn(II) complexes with N-(2-pyridinyl)morpholine-4-carbothioamide Polyhedron 2012, 38, 15-25 10.1016/j.poly.2012.02.017
43. Krivenko, L. V.; Sibgatullin, I. M.; Cherezova, E. N.; Galkin, V. I.; Mukmeneva, N. A. Correlation between the structure of thioureas and their reactivity toward hydroperoxides and peroxy radicals Russ. J. Gen. Chem. 2003, 73, 1086-1090 10.1023/B:RUGC.0000007616.03223.3a
44. Zhu, B.-Z.; Antholine, W. E.; Frei, B. Thiourea protects against copper-induced oxidative damage by formation of a redox-inactive thiourea-copper complex Free Radical Biol. Med. 2002, 32, 1333-1338 10.1016/S0891-5849(02)00847-X
45. Abbott, T. P.; Wohlman, A.; Isbell, T.; Momany, F. A.; Cantrell, C.; Garlotta, D. V.; Weisleder, D. 1,3-di(3-Methoxybenzyl) thiourea and related lipid antioxidants Ind. Crops Prod. 2002, 16, 43-57 10.1016/S0926-6690(02)00006-7
46. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95 10.1016/0006-2952(61)90145-9
47. Davalos, A.; Gomez-Cordoves, C.; Bartolome, B. Extending applicability of the oxygen radical absorbance capacity (ORAC-Fluorescein) assay J. Agric. Food Chem. 2004, 52, 48-54 10.1021/jf0305231
48. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 2001, 49, 4619-4626 10.1021/jf010586o
49. Hatip, F. F.; Suenaga, M.; Yamada, T.; Matsunaga, Y. Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Aβ40, by the β-sheet breaker peptides 16-23 and 17-24 Br. J. Pharmacol. 2009, 158, 1165-1172 10.1111/j.1476-5381.2009.00384.x
50. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. S.; Chen, P. P.; Kayed, R.; Glabe, C. G.; Frautschy, S. A.; Cole, G. M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 2005, 280, 5892-5901 10.1074/jbc.M404751200
51. Hensley, K.; Carney, J. M.; Mattson, M. P.; Aksenova, M.; Harris, M.; Wu, J. F.; Floyd, R. A.; Butterfield, D. A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 3270-3274 10.1073/pnas.91.8.3270
52. Dikalov, S. I.; Vitek, M. P.; Maples, K. R.; Mason, R. P. Amyloid β peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides J. Biol. Chem. 1999, 274, 9392-9399 10.1074/jbc.274.14.9392
53. Turnbull, S.; Tabner, B. J.; El-Agnaf, O. M. A.; Twyman, L. J.; Allsop, D. New evidence that the Alzheimer β-amyloid peptide does not spontaneously form free radicals: An ESR study using a series of spin-traps Free Radical Biol. Med. 2001, 30, 1154-1162 10.1016/S0891-5849(01)00510-X
54. Butterfield, D. A. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review Free Radical Res. 2002, 36, 1307-1313 10.1080/1071576021000049890
55. Goriya, Y.; Ramana, C. V. The [Cu]-catalyzed SNAR reactions: direct amination of electron deficient aryl halides with sodium azide and the synthesis of arylthioethers under Cu(II)-ascorbate redox system Tetrahedron 2010, 66, 7642-7650 10.1016/j.tet.2010.07.032
56. Guilloreau, L.; Combalbert, S.; Sournia-Saquet, A.; Mazarguil, H.; Faller, P. Redox chemistry of copper-amyloid-beta: the generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state ChemBioChem 2007, 8, 1317-1325 10.1002/cbic.200700111
57. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232 10.1016/S0223-5234(03)00012-6
58. Clark, D. E.; Pickett, S. D. Computational methods for the prediction of drug-likeness Drug Discovery Today 2000, 5, 49-58 10.1016/S1359-6446(99)01451-8
59. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
60. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249 10.1016/S1056-8719(00)00107-6
61. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55, 4877-4895 10.1021/jm201136z
62. Mao, F.; Kong, Q.; Ni, W.; Xu, X.; Ling, D.; Lu, Z.; Li, J. Melting point distribution analysis of globally approved and discontinued drugs: A research for improving the chance of success of drug design and discovery ChemistryOpen 2016, 5, 357-368 10.1002/open.201600015
63. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583 10.1021/jm060642i
64. Safer, D. J.; Allen, R. P. The central effects of scopolamine in man Biol. Psychiatry 1971, 3, 347-355
65. Klinkenberg, I.; Blokland, A. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies Neurosci. Biobehav. Rev. 2010, 34, 1307-1350 10.1016/j.neubiorev.2010.04.001
66. Brown, D. G.; Bernstein, P. R.; Griffin, A.; Wesolowski, S.; Labrecque, D.; Tremblay, M. C.; Sylvester, M.; Mauger, R.; Edwards, P. D.; Throner, S. R.; Folmer, J. J.; Cacciola, J.; Scott, C.; Lazor, L. A.; Pourashraf, M.; Santhakumar, V.; Potts, W. M.; Sydserff, S.; Giguere, P.; Levesque, C.; Dasser, M.; Groblewski, T. Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition J. Med. Chem. 2014, 57, 733-758 10.1021/jm4014828
67. Garcia-Barroso, C.; Ricobaraza, A.; Pascual-Lucas, M.; Unceta, N.; Rico, A. J.; Goicolea, M. A.; Salles, J.; Lanciego, J. L.; Oyarzabal, J.; Franco, R.; Cuadrado-Tejedor, M.; Garcia-Osta, A. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD Neuropharmacology 2013, 64, 114-123 10.1016/j.neuropharm.2012.06.052
68. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB J. Pharm. Sci. 2009, 98, 4429-4468 10.1002/jps.21745
69. Choi, J. S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 21990-21995 10.1073/pnas.1006091107
70. Mao, F.; Yan, J.; Li, J.; Jia, X.; Miao, H.; Sun, Y.; Huang, L.; Li, X. New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol Org. Biomol. Chem. 2014, 12, 5936-5944 10.1039/C4OB00998C